Could six months of treatment be enough? breast cancer trial tests shorter therapy
NCT ID NCT04928261
Summary
This study is testing whether 6 months of targeted therapy is as effective as the standard 12 months for patients with early-stage HER2-positive breast cancer. It focuses on patients who have already responded very well to their initial chemotherapy and targeted treatment, showing no remaining cancer at surgery. The goal is to see if a shorter treatment course can maintain good outcomes while reducing side effects, costs, and clinic visits.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, K1H8M2, Canada
Conditions
Explore the condition pages connected to this study.